Anavex Life Sciences Corp (AVXL)

[frrol]

Trevelyan is a pretty well known and intelligent biotech analyst, and has been quite skeptical of Cassava's research too:
https://ajtrev.substack.com/p/memory-games-part-i-the-data-is-available
He's pointing out things similar to Doc328's concerns: that we didn't use the most robust statistical tests (eg, one-sided t-test vs two-sided) making our p-val's literally less significant; and that we don't specify # of dropouts. He criticizes our use of SE instead of SD, but we're dealing with endpoint means of the individual scores not the scores themselves, so I don't see an issue there.

He smells a rat. To be fair to him, there are occasional shenanigans in biotechs' trial stats. It's one of the reasons you should know stats to be an investor in this sector, otherwise you can get misled. Biotech CEO's want to put the best spin reasonable on data. And their definition of "best spin reasonable" varies.

When you claim you "met all endpoints" on a very public TLR, but conspicuously under-report a primary endpoint, that's like bleeding in a pool of sharks. You better swim fast.